

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA

复星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

VOLUNTARY ANNOUNCEMENT THE PROGRESS OF THE PLAN FOR INCREASE IN SHAREHOLDING BY A CONTROLLING SHAREHOLDER

This announcement is made on a voluntary basis by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”).

Reference is made to the announcement of the Company dated 19 September 2019 (the “**Announcement**”) in relation to Shanghai Fosun High Technology (Group) Company Limited* (上海復星高科技(集團)有限公司) (“**Fosun High Tech**”), the controlling shareholder of the Company, increased its shareholding in the Company (including A Shares and/or H Shares) and the Shareholding Increase Plan. Unless otherwise specified, capitalized terms used herein shall have the same meaning ascribed to them in the Announcement.

On 18 March 2020, the Company was notified by Fosun High Tech regarding the progress of the Shareholding Increase Plan, and the details of which are as follows:

I. THE SHAREHOLDING INCREASE PLAN

Given the confidence about the future prospects for development of the Company and the recognition of the Company’s intrinsic value, Fosun High Tech intends to further increase its shareholding in the Company (including A Shares and/or H Shares) via the trading system of the Shanghai Stock Exchange (including the Shanghai-Hong Kong Stock Connect) by itself (and/or parties acting in concert with it) (the “**Shareholding Increase Party/Parties**”) within the 12 months commencing from 19 September 2019 (inclusive), if and where appropriate, the cumulative total amount thereof shall not be less than RMB100 million and the increased shareholding percentage of Fosun High Tech and parties acting in concert with it in aggregate shall not exceed 2% of total issued shares of the Company as at 19 September 2019 (i.e 2,562,898,545 shares), and the aggregated number of shares in the Company to be acquired in the 12-month period shall not exceed 2% of the total number of issued shares in the Company. The detailed plan (including but not limited to the specific amount and number of shares of the shareholding increase) shall be

determined based on the market conditions and the Company's share price. In the event of any exentitlement or exdividend event in respect of the Company during the term of the Shareholdings Increase Plan, including but not limited to bonus issue, capital increase, issue of new shares or rights issue, the relative adjustment will be made to the Shareholding Increase Plan according to the change of share capital and will disclose the same in a timely manner accordingly. The funds required for the Shareholding Increase Plan are self-owned funds of the Shareholding Increase Parties.

II. THE PROGRESS OF THE SHAREHOLDING INCREASE PLAN

As at 18 March 2020, it has passed halfway period of the Shareholding Increase Plan. From 19 September 2019 to 18 March 2020, Fosun High Tech acquired through the Shanghai-Hong Kong Stock Connect trading system of the Shanghai Stock Exchange an aggregate number of 7,116,000 H Shares for an aggregate amount of approximately RMB148.9894 million, with the increased shareholding percentage of Fosun High Tech in aggregate represents approximately 0.28% of the total issued shares of the Company as at the date of this announcement (i.e 2,562,898,545, the same for below).

As at 18 March 2020 (after trading hours), Fosun High Tech held an aggregate of 977,644,790 shares of the Company (including 938,095,290 A Shares and 39,549,500 H Shares), representing approximately 38.15% of the total issued shares of the Company as at the date of this announcement.

III. The Shareholding Increase Plan complies with the provisions of the Securities Law of the People's Republic of China and other applicable laws, regulations, department regulations and the relevant rules of Shanghai Stock Exchange and The Stock Exchange of Hong Kong Limited.

IV. Fosun High Tech undertakes that it and/or the parties acting in concert with it will not reduce its shareholding in the Company during the implementation of Shareholding Increase Plan and within the statutory restricted period.

- V. The Company will continue to pay attention to the situation regarding the shareholding increase in the Company by Shareholding Increase Party/Parties and make timely disclosure of the relevant information pursuant to the relevant regulations under the Rules Governing the Listing of Stocks on Shanghai Stock Exchange, Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, Measures for the Administration of the Takeover of Listed Companies and Guidelines for the Increase in Shareholdings by Shareholders of Listed Companies and Persons Acting in Concert with Such Shareholders of Shanghai Stock Exchange.

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Qiyu
Chairman

Shanghai, the People's Republic of China

18 March 2020

As at the date of this announcement, the executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang and Mr. Wu Yifang; the non-executive directors of the Company are Mr. Xu Xiaoliang and Ms. Mu Haining; and the independent non-executive directors of the Company are Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin, Ms. Li Ling and Mr. Tang Guliang.

* *for identification purposes only*